Efficacy and safety results from a randomized, phase II trial of neoadjuvant capecitabine plus epirubicin plus cyclophosphamide vs 5-FU + epirubicin plus cyclophosphamide in operable breast cancer

被引：0
|
作者：
Roche, H.
Penault-Llorca, F.
Berton, Rigaud D.
Tubiana, Mathieu N.
Ferrero, J. M.
Coudert, B.
Mousseau, M.
Monnier, A.
Orfuevre, H.
Audhuy, B.
Rotarski, M.
Homokos, H.
Fumoleau, P.
机构：
[1] Inst Claudius Regaud, Toulouse, France
[2] Ctr Jean Perrin, Clermont Ferrand, France
[3] Ctr Rene Gauducheau, St Herblain, France
[4] Hop Dupuytren, Limoges, France
[5] Ctr Antoine Lacassagne, F-06054 Nice, France
[6] Ctr Georges Francois Leclerc, Dijon, France
[7] CHU Grenoble, La Tronche, France
[8] CH Montbeliard, Montbeliard, France
[9] CH Fleyriat, Bourg En Bresse, France
[10] Hop Louis Pasteur, Colmar, France
[11] Ctr Oncol Du Pays Basque, Bayonne, France
[12] Roche Neuilly, Neuilly Sur Seine, France
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S225 / S225
页数：1
相关论文
共 50 条
  • [21] First interim analysis of a randomized trial comparing capecitabine/epirubicin/cyclophosphamide (XEC) vs 5-FU/epirubicin/cyclophosphamide (FEC) as adjuvant therapy for medium- or high-risk early breast cancer (EBC)
    Shao, Z.
    Huang, B.
    Zhang, J.
    Zhou, S.
    He, P.
    Chen, D.
    Cui, S.
    Ren, C.
    Cai, L.
    Shi, J.
    EJC SUPPLEMENTS, 2010, 8 (03): : 64 - 64
  • [22] Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
    Jones, Stephen E.
    Savin, Michael A.
    Holmes, Frankie Ann
    O'Shaughnessy, Joyce A.
    Blum, Joanne L.
    Vukelja, Svetislava
    McIntyre, Kristi J.
    Pippen, John E.
    Bordelon, James H.
    Kirby, Robert
    Sandbach, John
    Hyman, William J.
    Khandelwal, Pankaj
    Negron, Angel G.
    Richards, Donald A.
    Anthony, Stephen P.
    Mennel, Robert G.
    Boehm, Kristi A.
    Meyer, Walter G.
    Asmar, Lina
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5381 - 5387
  • [23] Predictive factors of anthracycline or taxan based chemotherapy: Analysis from a randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer
    Ishikawa, Takashi
    Narui, Kazutaka
    Shimada, Kazuhiro
    Kida, Kumiko
    Sugae, Sadatoshi
    Ichikawa, Yasushi
    Tanabe, Mikiko
    Endo, Itaru
    Oba, Mari S.
    CANCER RESEARCH, 2014, 74 (19)
  • [24] A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer. Kanagawa breast oncology group (KBOG) 1101 study
    Ishikawa, T.
    Shimizu, D.
    Tanabe, M.
    Oba, M. S.
    Sasaki, T.
    Morita, S.
    Kida, K.
    Nawata, S.
    Mogami, M.
    Doi, T.
    Tsugawa, K.
    Ogata, H.
    Kosaka, Y.
    Sengoku, N.
    Saito, Y.
    Suzuki, Y.
    Suto, A.
    Chishima, T.
    Ichikawa, Y.
    Endo, I.
    Tokuda, Y.
    CANCER RESEARCH, 2013, 73
  • [25] First safety data from a randomised phase III trial comparing adjuvant epirubicin-cyclophosphamide → docetaxel (EC → T) vs ET capecitabine (X) in N plus operable breast cancer (BC)
    Martin, M.
    Lluch, A.
    Ruiz-Simon, A.
    Ribelles, N.
    Ruiz-Borrego, M.
    Rodriguez-Lescure, A.
    Munoz, M.
    Ramos, M.
    Gonzalez, S.
    Margeli, M.
    BREAST, 2009, 18 : S55 - S55
  • [26] Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial
    Zhang, Liulu
    Wu, Zhi-Yong
    Li, Jie
    Lin, Ying
    Liu, Zhenzhen
    Cao, Yin
    Zhang, Gangling
    Gao, Hong-Fei
    Yang, Mei
    Yang, Ci-Qiu
    Zhu, Teng
    Cheng, Min-Yi
    Ji, Fei
    Li, Jieqing
    Wang, Kun
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (04) : 654 - 662
  • [27] A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer
    Carmichael, J
    Jones, A
    Hutchinson, T
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 44 - 47
  • [28] Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial
    Joensuu, Heikki
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Huovinen, Rukka
    Jukkola-Vuorinen, Arja
    Tanner, Minna
    Asola, Raija
    Kokko, Riitta
    Ahlgren, Johan
    Auvinen, Paivi
    Hemminki, Akseli
    Paija, Outi
    Helle, Leena
    Nuortio, Lauri
    Villman, Kenneth
    Nilsson, Greger
    Lahtela, Sirpa-Liisa
    Lehtio, Kaisa
    Pajunen, Marjo
    Poikonen, Paula
    Nyandoto, Paul
    Kataja, Vesa
    Bono, Petri
    Leinonen, Mika
    Lindman, Henrik
    LANCET ONCOLOGY, 2009, 10 (12): : 1145 - 1151
  • [29] CISPLATINUM PLUS EPIRUBICIN ALTERNATED WITH CYCLOPHOSPHAMIDE PLUS 5-FLUOROURACIL IN OVARIAN-CANCER
    MARTONI, A
    ERCOLINO, L
    BELLUCCO, A
    CANOVA, N
    LELLI, G
    PANNUTI, F
    JOURNAL OF CHEMOTHERAPY, 1990, 2 (01) : 62 - 66
  • [30] Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial
    Tokunaga, Shinya
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Kawajiri, Hidemi
    Tokumoto, Mao
    Nishimura, Shigehiko
    Nishimori, Takeo
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Yamagata, Shigehito
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2019, 39 (04) : 2053 - 2059
12345